Stratos Wealth Advisors LLC Buys 621 Shares of Pfizer Inc. (NYSE:PFE)

Stratos Wealth Advisors LLC grew its position in Pfizer Inc. (NYSE:PFE) by 0.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 111,559 shares of the biopharmaceutical company’s stock after purchasing an additional 621 shares during the quarter. Stratos Wealth Advisors LLC’s holdings in Pfizer were worth $3,229,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the company. Olistico Wealth LLC bought a new stake in Pfizer in the 2nd quarter valued at about $25,000. MFA Wealth Advisors LLC acquired a new stake in shares of Pfizer in the second quarter valued at approximately $29,000. Quarry LP acquired a new stake in Pfizer during the second quarter worth approximately $31,000. Trivant Custom Portfolio Group LLC increased its stake in Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares during the period. Finally, Financial Connections Group Inc. acquired a new position in Pfizer in the 2nd quarter valued at $34,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of several analyst reports. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. UBS Group upped their price target on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Wells Fargo & Company lifted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Finally, Barclays upped their target price on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Pfizer has an average rating of “Moderate Buy” and an average target price of $33.91.

Pfizer Price Performance

Shares of PFE opened at $29.22 on Friday. The business has a 50-day simple moving average of $29.07 and a two-hundred day simple moving average of $28.44. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $31.54. The stock has a market cap of $165.58 billion, a PE ratio of -487.00, a PEG ratio of 1.02 and a beta of 0.67. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. During the same period last year, the company earned $0.67 EPS. The firm’s revenue was up 2.1% compared to the same quarter last year. Analysts anticipate that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 5.75%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio is currently -2,800.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.